A new bifunctional NTB (tris(benzimidazol-2-ylmethyl)amine)-type ligand incorporating coordination discriminable tripodal benzimidazolyl and monodentate pyridyl groups, tris((pyridin-3-ylmethyl)benzoimidazol-2-ylmethyl)amine (3-TPyMNTB), has been prepared to assemble 4d–4f heterometallic three-dimensional metal–organic frameworks (MOFs) in a stepwise route: (1) direct reaction of 3-TPyMNTB with Ln(ClO4)3 affords monomeric complexes [Eu(3-TPyMNTB)2](ClO4)3·2.5MeCN (1-Eu) and [Gd(3-TPyMNTB)2](ClO4)3·2MeCN·2CHCl3 (1-Gd), and (2) assembly of the precursors 1-Eu and 1-Gd with AgClO4 gives rise to infinite MOFs [EuAg3(3-TPyMNTB)2(H2O)(MeCN)](ClO4)6·4MeCN (2-Eu-Ag) and [GdAg3(3-TPyMNTB)2(H2O)(MeCN)](ClO4)6·4MeCN (2-Gd-Ag), respectively. In monomer 1-Eu, the ligand shows an antenna effect to transfer absorbed energy to Eu3+ center to emit characteristic red luminescence, while in 4d–4f heterometallic MOF 2-Eu-Ag, the ligand centered emission is resensitized by Ag+ ions to generate dual emissions, coming up with the direct white-light emission from a single crystal. The detailed photoluminescent study has been carried out in both solid state and solution to elucidate the emission nature.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: